| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/IMT.15.29 |
| P698 | PubMed publication ID | 26100270 |
| P50 | author | Soudeh Ghafouri-Fard | Q38548826 |
| P2093 | author name string | Ali Esfandiary | |
| P2860 | cites work | MAGE-RING Protein Complexes Comprise a Family of E3 Ubiquitin Ligases | Q24300816 |
| An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12 | Q24300914 | ||
| A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma | Q24319940 | ||
| A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening | Q24564781 | ||
| Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes | Q24680097 | ||
| A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer | Q24796746 | ||
| Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells | Q24804892 | ||
| mRNA expression of tumor-associated antigens in melanoma tissues and cell lines | Q28218733 | ||
| Expression of Melan-A/MART-1 in primary melanoma cell cultures has prognostic implication in metastatic melanoma patients | Q28276580 | ||
| Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer | Q28282730 | ||
| Expression of MAGE genes in primary and metastatic cutaneous melanoma | Q28291687 | ||
| Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients | Q33797051 | ||
| Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients | Q33797133 | ||
| Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. | Q33892426 | ||
| A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. | Q33943139 | ||
| MAGE-A family: attractive targets for cancer immunotherapy | Q34217938 | ||
| Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma | Q34503895 | ||
| Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma | Q34743450 | ||
| Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma | Q34870799 | ||
| Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells | Q44662354 | ||
| MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors | Q45138010 | ||
| MAGE-A3 is a frequent tumor antigen of metastasized melanoma | Q45167053 | ||
| Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells | Q45428921 | ||
| Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus | Q45710740 | ||
| High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies | Q45888192 | ||
| Melanoma antigen encoding gene-A3 expression, its clinical significance, and its risk of developing acute myeloid leukemia. | Q45990205 | ||
| A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells | Q46366455 | ||
| The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma | Q46778780 | ||
| Novel immunodominant epitopes derived from MAGE-A3 and its significance in serological diagnosis of gastric cancer | Q48030870 | ||
| Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer | Q49096862 | ||
| MAGE-A3 with cell-penetrating domain as an efficient therapeutic cancer vaccine. | Q50674851 | ||
| Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. | Q50954464 | ||
| Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. | Q50954469 | ||
| Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. | Q51024694 | ||
| Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. | Q51611724 | ||
| Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer. | Q51630614 | ||
| Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. | Q51829598 | ||
| Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. | Q51842445 | ||
| Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy. | Q52933889 | ||
| Induction of cytotoxic T cells as a novel independent survival factor in malignant melanoma with percutaneous peptide immunization. | Q53052831 | ||
| Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression. | Q53762262 | ||
| Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma. | Q54332852 | ||
| Expression of MAGE-A3/6 in primary breast cancer is associated with hormone receptor negative status, high histologic grade, and poor survival. | Q54378690 | ||
| Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. | Q54415254 | ||
| Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. | Q54574332 | ||
| Polyclonal CTL Responses Observed in Melanoma Patients Vaccinated with Dendritic Cells Pulsed with a MAGE-3.A1 Peptide | Q54747960 | ||
| High frequency of expression of MAGE genes in human hepatocellular carcinoma. | Q57205523 | ||
| Expression of cancer/testis (CT) antigens in lung cancer | Q58454722 | ||
| The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research | Q35000726 | ||
| MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin | Q35091212 | ||
| A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). | Q35238022 | ||
| Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis | Q35733359 | ||
| Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells | Q36018407 | ||
| Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma | Q36075245 | ||
| Cancer-testis antigen expression and immunogenicity in AL amyloidosis | Q36289604 | ||
| Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. | Q36370290 | ||
| Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma | Q36375683 | ||
| High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens | Q36402611 | ||
| Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming | Q36446446 | ||
| Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma | Q36619878 | ||
| Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy | Q36637039 | ||
| Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells | Q37352612 | ||
| A Mage3/Heat Shock Protein70 DNA vaccine induces both innate and adaptive immune responses for the antitumor activity | Q37461025 | ||
| Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen | Q37570169 | ||
| Expression of cancer-testis genes in brain tumors: implications for cancer immunotherapy. | Q37965751 | ||
| Immunotherapy in nonmelanoma skin cancer | Q38014084 | ||
| Tumor-specific MAGE proteins as regulators of p53 function | Q38016001 | ||
| Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients. | Q38403243 | ||
| Helicobacter pylori, a carcinogen, induces the expression of melanoma antigen-encoding gene (Mage)-A3, a cancer/testis antigen | Q39317988 | ||
| Targeting the MAGE A3 antigen in pancreatic cancer | Q39318470 | ||
| Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma | Q39358663 | ||
| Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma | Q39398399 | ||
| Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis | Q39456290 | ||
| Selective cancer-germline gene expression in pediatric brain tumors | Q39609814 | ||
| Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells | Q39762419 | ||
| Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination | Q39802886 | ||
| Cancer testis antigen expression in gastrointestinal stromal tumors: new markers for early recurrence | Q40068024 | ||
| Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells | Q40281482 | ||
| Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein. | Q40460679 | ||
| Primary malignant melanoma of the oesophagus: a clinical and pathological study with emphasis on the immunophenotype of the tumours for melanocyte differentiation markers and cancer/testis antigens | Q40611491 | ||
| Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes | Q40614042 | ||
| Expression of the melanoma antigen-encoding gene in human lung cancer | Q40868308 | ||
| Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen | Q41870799 | ||
| Quantitative expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tract cancer. | Q41977456 | ||
| Melanoma gene expression and clinical course | Q44164197 | ||
| Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients | Q44409145 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 683-704 | |
| P577 | publication date | 2015-06-23 | |
| P1433 | published in | Immunotherapy | Q18713038 |
| P1476 | title | MAGE-A3: an immunogenic target used in clinical practice | |
| P478 | volume | 7 |
| Q36309496 | Cancer stem cell vaccine expressing ESAT-6-gpi and IL-21 inhibits melanoma growth and metastases |
| Q64096332 | Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects |
| Q60920880 | Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets |
| Q60313491 | Cancer/testis Antigen MAGEA3 Interacts with STAT1 and Remodels the Tumor Microenvironment |
| Q47876991 | Expression analysis of cancer-testis genes in prostate cancer reveals candidates for immunotherapy |
| Q40333429 | GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth. |
| Q26774913 | Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens |
| Q37286552 | In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer. |
| Q91983276 | LINC01234/MicroRNA-31-5p/MAGEA3 Axis Mediates the Proliferation and Chemoresistance of Hepatocellular Carcinoma Cells |
| Q47601811 | Long Non Coding RNA Expression Intersecting Cancer and Spermatogenesis: A Systematic Review |
| Q98289749 | MAGEA3 promotes proliferation and suppresses apoptosis in cervical cancer cells by inhibiting the KAP1/p53 signaling pathway |
| Q50070352 | Melanoma: a prototype of cancer-testis antigen-expressing malignancies |
| Q89125347 | Negative but not futile: MAGE-A3 immunotherapeutic for melanoma |
| Q92639851 | Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review |
| Q59135044 | Urine exosome gene expression of cancer-testis antigens for prediction of bladder carcinoma |
| Q53760783 | [Research Progress of Exosomes in Lung Cancer Diagnosis and Treatment]. |
Search more.